EUCTR2005-003048-78-FI进行中（未招募）不适用
Full title of the trial: A 9 Week, Randomized, Double-Blind, placebo-controlled, Multicenter, Study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic pain
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Oy
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- •·Male or female subjects, ages between 18-80 years;
- •·Signed and dated informed consent;
- •·Females of childbearing potential must have a negative serum ß-HCG pregnancy test and be practicing an effective form of contraception (accepted methods are hormonal [oral contraceptive or injectable contraceptive], double barrier with spermicide, or intrauterine device-IUD). Complete abstinence may be considered acceptable, but must first be discussed on a case-by-case basis with the Pfizer Clinical Study Operation Manager/Project Manager or Clinician prior to any screening tests or procedures for the study;
- •·Diagnosis of Posttraumatic Peripheral Neuropathic Pain (NeP) syndrome, including post-surgical NeP, NeP due to peripheral nerve injury, and phantom limb pain, confirmed by a qualified pain specialist and persisting for a minimum of 3 months following the traumatic event;
- •·Must complete =4 daily pain diaries during the last week of the screening period prior to randomization;
- •·Must have a daily mean pain score of =4 over the screening period prior to randomization based on Daily Pain Rating Scale (DPRS);
- •·Must have a score of >40 mm on the Visual Analogue Scale (VAS) of the SF-MPQ.
- •·Screening laboratory values within normal limits, or abnormalities clinically insignificant in the judgment of the investigator; and
- •·Deemed capable of complying with study schedule, procedures and medications.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects presenting with any of the following will not be included in the trial:
- •·Pregnant or lactating women or women of childbearing potential not using acceptable method of contraception;
- •·Subjects with neuropathic pain that is not due to trauma; eg, subjects with DPN, PHN, radiculopathy, trigeminal neuralgia (TGN), or carpal tunnel syndrome (CTS);
- •·Subjects whose posttraumatic neuropathic pain is central rather than peripheral (eg, spinal cord injury);
- •·Subjects whose posttraumatic neuropathic pain is due to Complex Regional Pain Syndrome (CRPS, Type I or Type II);
- •·Skin conditions in the affected dermatome that (in the judgment of the investigator) could interfere with evaluation of neuropathic pain condition;
- •·Current or past DSM-IV-TRTM (2000) diagnosis of schizophrenia, psychotic disorder, bipolar affective disorder or obsessive-compulsive disorder, and Major Depressive Disorder (MDD);
- •·Current or past DSM-IV-TRTM (2000) diagnosis of substance abuse or dependence within the last 6 month;
- •·Use of gabapentin during the study. Discontinuation of gabapentin at the screening visit is permitted;
- •·Initiate specific behavioural or supportive therapy for any anxiety disorder post randomization;
- •·Clinically significant or unstable conditions that, in the opinion of the investigator, would compromise participation in the study. This includes, for example, medical conditions such as, but not limited to: hepatic, renal, respiratory, hematologic, immunologic, or cardiovascular diseases (eg, myocardial infarction within previous month, ventricular arrhythmia recent severe heart insufficiency), inflammatory or rheumatologic disease, active infections, symptomatic peripheral vascular disease, and untreated endocrine disorders;
- •·History of seizure disorder, except febrile seizures of childhood;
- •·Any other condition, which in the investigator’s judgment might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study. This includes any condition precluding pregabalin use;
- •·Malignancy within past 2 years with exception of basal cell carcinoma;
- •·Urine screen positive for illicit substances at screening (Visit 1);
- •·Have ever received treatment with vigabatrin, hydroxychloroquine, deferoxamine, thiorizidine and or any compound known to adversely affect retina and visual fields;
- •·CLcr =60 mL/min (estimated by the central laboratory from serum creatinine, body weight, age, and sex using the Cockroft-Gault equation. (See Appendix A);
- •·White blood cells (WBC) <2500/mm³; neutrophil count <1500/mm³; platelet count <100 x10³/mm³;
- •·Liver function tests >3 x the upper limit of normal is considered clinically significant;
- •·A previous history of intolerance or hypersensitivity to pregabalin, gabapentin or drugs with similar chemical structure;
- •·Galactose intolerance, lactase deficiency and/or any other malabsorption syndromes;
- •·Anticipated need for surgery during the study or within 4 weeks of completion;
- •·Anticipated need for general anesthetics during the course of the study;
- •·Anticipated need for hospitalization for any reason during the course of the study or within 4 weeks of completion;
- •·Participation in a previous pregabalin clinical trial or previous prescribed use of pregabalin (in countries where it is commercially available);
- •·Participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study; and/or
研究者
相似试验
进行中（未招募）
不适用
Full title of the trial: A 9 Week, Randomized, Double-Blind, placebo-controlled, Multicenter, Study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic paiEUCTR2005-003048-78-SEPfizer AB260
进行中（未招募）
不适用
A 9-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, STUDY OF PREGABALIN BID IN SUBJECTS WITH POSTTRAUMATIC PERIPHERAL NEUROPATHIC PAITreatment of post-traumatic peripheral neuropathic pain in adultsMedDRA version: 6.1Level: PTClassification code 10034586EUCTR2005-003048-78-ITPFIZER260
进行中（未招募）
1 期
Full title of the trial :52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional insulin regimen in type 2 diabetes mellitus patients with poor glycemic control pretreated with a two-injection conventional insulin therapy - GINGER-StudyDiabetes mellitus type 2Classification code 10012613EUCTR2004-001287-49-CZAventis Pharma Deutschland GmbH372
已完成
2 期
EFFECT OF VSL#3 IN PATIENTS WITH MICROSCOPIC COLITISCTRI/2008/091/000086CD Pharma India Pvt Ltd30
进行中（未招募）
不适用
Ensayo de 12 semanas de duración, aleatorizado, doble ciego, controlado con placebo, destinado a evaluar la eficacia y la seguridad de prucaloprida en sujetos con dolor crónico no oncológico que padecen estreñimiento causado por opioidesestreñimiento causado por opioides en sujetos con dolor crónico no oncológicoMedDRA version: 12.1Level: LLTClassification code 10010774Term: ConstipationEUCTR2009-015652-20-ESMovetis NV510